Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0043—Nose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
  • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P23/00—Anaesthetics
  • A61P23/02—Local anaesthetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

• the present invention relates to imidiazotriazinone-containing compositions for nasal application which, in addition to the imidazotriazinon, contain a small amount of
• Cyclic guanosine-3 ⁇ 5'-monophosphate phosphodiesterase inhibitors have a known spectrum of action (cf. e.g. EP-A-0 463 756, WO 99/24433).
• the imidazotriazinones encompassed by the present invention are described in WO 99/24433 as such cGMP PDE inhibitors.
• the biochemical foundations of the process of penile erection were clarified a few years ago and it was described on the basis that cGMP-PDE inhibitors, in particular PDE5 inhibitors, are suitable for the treatment of male erectile dysfunction (cf. Rajfer et al., New England J. Med. 326
• WO 94/28902 then described the use of certain cGMP-PDE inhibitors for the treatment of male erectile dysfunction, one of which (sildenafil citrate, Viagra ® ) has now been approved as an orally administrable medication for this indication.
• cGMP-PDE inhibitors for the treatment of male erectile dysfunction, one of which (sildenafil citrate, Viagra ® ) has now been approved as an orally administrable medication for this indication.
• one disadvantage of oral administration is that it is delayed
• first-pass effects or food effects can impair the effectiveness of the orally administered drug.
• EP-A-0 967 214 the nasal application of a more water-soluble salt of Sildenafil, namely of sildenafil mesylate, and the achievable faster active ingredient flooding in the bloodstream with a smaller required amount of active ingredient compared to the oral route are described.
• WO 99/15177 describes liquid-crystalline nicotine preparations to which a local anesthetic is added in order to avoid adverse effects of the nicotine, which are caused by its local irritant effect.
• the local anesthetic works by blocking peripheral pain receptors.
• cGMP PDE inhibitors do not, or only to a small extent, produce such a local irritant effect when administered nasally.
• GB-A-2 315 673 has proposed the intranasal application of local anesthetics such as lidocaine in addition to a 5-HTID agonist for the treatment of migraines.
• local anesthetics such as lidocaine
• this proposal is based on the vasodilating effect of local anesthetics, which leads to an accelerated absorption of the 5-HT1D agonist and thus to a faster onset of action.
• composition which comprises at least one imidiazotriazinon and at least one local anesthetic, the local anesthetic not being benzyl alcohol.
• the cGMP PDE inhibitor contained in the compositions is a compound of the formula (I) in which
• R 1 represents hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms
• R 2 represents straight-chain alkyl having up to 4 carbon atoms
• R 3 and R 4 are identical or different and represent a straight-chain or branched alkyl chain with up to 5 carbon atoms, which is optionally substituted up to twice the same or different by hydroxy or methoxy,
• R 3 and R 4 together with the nitrogen atom represent a piperidinyl, morpholinyl,
• R 7 is hydrogen, formyl, straight-chain or branched acyl or alkoxycarbonyl each having up to 6 carbon atoms, or straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally one to two times, identical or different by hydroxy, carboxyl straight-chain or branched alkoxy or alkoxycarbonyl, each having up to 6 carbon atoms, or is C 3-8 cycloalkyl,
• R 3 and R 4 formed together with the nitrogen atom, optionally one to two times, the same or different, optionally also geminal, by hydroxy, formyl, carboxyl, straight-chain or branched acyl or alkoxycarbonyl each having up to 6 carbon atoms are substituted,
• R ⁇ and R ⁇ and formed together with the nitrogen atom are optionally substituted by straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally mono- or disubstituted, identically or differently, by hydroxyl, carboxyl,
• R 5 and R 6 are the same or different and represent hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms, hydroxyl or straight-chain or branched alkoxy having up to 6 carbon atoms,
• compositions which, as cGMP PDE inhibitor, 2- ⁇ 2-ethoxy-5 - [(4-ethylpiperazin-l-yl) sulfonyl] phenyl ⁇ -5-methyl-7-propylimidazo [5, lf] [l , 2,4] triazin-4 (3H) -one (vardenafil), or their pharmaceutically acceptable salts, isomers and or hydrates such as the corresponding hydrochloride, hydrochloride trihydrate, citrate or mesylate.
• the compounds of formula (I) can be prepared, for example, as described in WO 99/24433.
• Alkyl generally represents a straight-chain or branched hydrocarbon radical having 1 to 6 carbon atoms. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, hexyl, isohexyl.
• Acyl generally represents straight-chain or branched lower alkyl having 1 to 6 carbon atoms, which is bonded via a carbonyl group. Examples include: acetyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl and isobutylcarbonyl.
• Alkoxy generally represents a straight-chain or branched hydrocarbon radical having 1 to 6 carbon atoms which is bonded via an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy isopentoxy, hexoxy, isohexoxy.
• alkoxy and alkyloxy are used synonymously.
• Alkoxycarbonyl can, for example, by the formula
• Alkyl here generally represents a straight-chain or branched hydrocarbon radical having 1 to 6 carbon atoms.
• Alkyl here generally represents a straight-chain or branched hydrocarbon radical having 1 to 6 carbon atoms.
• Alkoxycarbonyl radicals called: methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl or isobutoxycarbonyl.
• Cycloalkyl generally represents a cyclic hydrocarbon radical having 3 to 8 carbon atoms. Cyclopropyl, cyclopentyl and cyclohexyl are preferred.
• Examples include cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
• heterocycle generally represents a saturated, unsaturated or aromatic 3- to 6-membered, for example 5- or 6-membered, heterocycle which can contain up to 3 heteroatoms from the series S, N and / or O and which in the case of a nitrogen atom can also be bound via this.
• Examples include: oxadiazolyl, thiadiazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, furyl, pyrrolyl, pyrrolidinyl, piperazinyl, tetrahydropyranyl, tetrahydrofuranyl, 1,2,3 triazolyl, thiazolyl, oxazolyl, morpholol, imidazolyl, imaz. Thiazolyl, furyl, oxazolyl, pyrazolyl,
• heteroaryl stands for an aromatic heterocyclic radical.
• Physiologically acceptable salts are preferred in the context of the present invention.
• Physiologically acceptable salts of the compounds according to the invention can be salts of the substances according to the invention with mineral acids, carboxylic acids or
• Be sulfonic acids are particularly preferred. Particularly preferred are, for example, salts with hydrochloric acid, Hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid as well as sugar acids such as glucuronic acid or lactobionic acid.
• hydrochloric acid Hydrobromic acid
• sulfuric acid sulfuric acid
• phosphoric acid methanesulfonic acid
• methanesulfonic acid ethanesulfonic acid
• p-toluenesulfonic acid benzenesulfonic acid
• benzenesulfonic acid naphthalenedisulfonic acid
• acetic acid
• Physiologically acceptable salts can also be metal or ammonium salts of the compounds according to the invention which have a free carboxyl group.
• metal or ammonium salts of the compounds according to the invention which have a free carboxyl group.
• Sodium, potassium, magnesium or calcium salts as well as ammonium salts derived from ammonia, or organic amines such as ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine or ethylenediamine ,
• the compounds of formula (I) can exist in isomeric forms. According to the present invention, these include stereoisomeric forms that are either like image and mirror image (enantiomers) or that are not like image and mirror image
• Diastereomers behave to understand.
• the invention relates both to the enantiomers or diastereomers and to their respective mixtures.
• the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner, for example by racemate resolution or chromatographic separation.
• Double bonds present in the compounds according to the invention can be in the eis or trans configuration (Z or E form).
• the compounds of the formula (I) can also be in the form of hydrates, both hydrates of the free compounds and hydrates of their salts being included according to the present invention.
• An example of a hydrate of a salt is
• compositions according to the invention to be administered nasally are preferably only amounts of 0.001 mg / kg to 0.5 mg / kg of cGMP
• the local anesthetics which can be used according to the invention are known per se and are listed, for example, in Remington's Pharmaceutical Sciences 1990, pp. 1048-1056. Local anesthetics are compounds that reversibly affect the excitability of sensory nerve endings or the neuronal conductivity for pain or other sensory
• Preferred local anesthetics according to the present invention are compounds of the formula (II)
• R 1 is H, NH 2 , NH (C 1-6 alkyl), O-C ⁇ -6 - alkyl or CH 2 OPh;
• R stands for OC 1-6 alkyl, which may be a radical from the group consisting of NH (C ⁇ -6 - alkyl), N (C 1-6 -A_kyl) or a saturated 5- or six-membered heterocycle, which is at least one Contains nitrogen atom and is bound via this and optionally one or two further hetero- atoms from the group consisting of N, O, S, and optionally carries one to three further -6 alkyl C ⁇ , may comprise, or
• Het stands for (CH 2 ) 1-6 -Het, where Het stands for a saturated 5-membered or six-membered heterocycle which contains at least one nitrogen atom and is bonded thereto and optionally one or two further heteroatoms from the group consisting of N, O , S, and optionally carries one to three further C 1-6 alkyl radicals;
• R 3 represents H, halogen or OC 1-6 alkyl
• R 1 represents H or OH
• R 2 represents C 1-6 alkyl-N (C 1-6 alkyl) 2 , where the bridging alkyl chain can optionally carry one or more C 1-6 alkyl radicals, or represents a saturated 5 or 6-membered heterocycle, which contains at least one nitrogen atom and optionally carries one or two further heteroatoms from the group consisting of N, O, S and optionally one to three further C 1-6 alkyl radicals,
• R J is C 1-6 alkyl, halogen or COOC 1-6 alkyl; n represents 1 or 2;
• R 1 represents H, NH 2 , NH-nC 4 H 9 , OnC 3 H 7 , OnC 4 H 9 or CH 2 OPh;
• O (CH 2 ) 2 N (CH 3 ) 2 or a radical from the group consisting out
• R 3 represents H, CI, OnC 3 H 7 or OnC 4 H 9 ; or compounds of the formula (III)
• R 1 represents H or OH
• R 2 for CH 2 N (C 2 H 5 ) 2 , CHCH 3 NH-nC 3 H 7 , CH 2 NH-nC 4 H 9 or a radical from the group consisting of
• R J is CH 3 , CI or COOCH 3 ;
• n 1 or 2;
• the following can particularly preferably be used as local anesthetics: benzocaine, butambene, piperocaine, piperocaine hydrochloride, procaine,
• These compounds are commercially available or can be prepared in a manner known to the person skilled in the art, for example as described in JL McGuire (ed.), Pharmaceuticals, Volume 2, Wiley-VCH 2000, p. 539 ff.
• benzocaine, lidocaine, tetracaine, benoxinate, polidocanol or their pharmaceutically acceptable salts can preferably be used as local anesthetics.
• Lidocaine hydrochloride or lidocaine methanesulfonate are particularly preferred according to the invention.
• the benzyl alcohol sometimes referred to as the local anesthetic is not covered by the subject matter of the present invention, since it has not proven to be suitable for overcoming the disadvantages described above and additionally led to local irritation on the nasal mucosa.
• compositions according to the invention contain the local anesthetic (s) in a lower concentration than the standard amount of commercially available topical preparations for surface anesthesia, namely in a concentration of less than 4% (m / v), preferably less than 3% (m / v), where% (m / v) stands for% mass / volume, ie 3% (m / v) means, for example, 3 g of substance in 100 ml of solution.
• lidocaine is contained in the compositions according to the invention in a concentration of less than 4% (m / v), preferably from 0.5 to 3.0% (m / v), which when administered
• volume of 100 ul corresponds to a single dose of less than 4 mg, preferably 0.5-3 mg. This is below the concentration of lidocaine in the commercial product Xylocaine ® 4%, which contains 200 mg lidocaine per 5 ml volume for surface anesthesia in the ear, nose and throat area (Rote Liste 1999, Editio Cantor, Aulendorf).
• oxybuprocaine (benoxinate) in the compositions according to the invention is in a concentration of less than 1%. (m / v) (corresponding to a single dose of 0.5 mg / 50 ⁇ l), preferably 0.1-0.8% (m / v).
• tetracaine is contained in the compositions according to the invention in a concentration of less than 0.5 mg per single dose, preferably to less than 0.25 mg per single dose.
• up to 20 mg of tetracin is recommended for nasal mucosal anesthesia (Reynolds 1990, cited in: Drugdex Drag Evaluations, Micromedex 2001, Engelwood, Colorado, USA).
• compositions according to the invention can be formulated as a solution, suspension, emulsion or powder for atomization in order to be sprayed into the nose, sucked in, dripped or applied to the nasal mucous wall. Wording in
• a solution, suspension for example a nanoparticle suspension, or emulsion
• a drip preparation for example from a nasal dropper bottle or a pipette, pump spray or compressed gas pack (for example an aerosol or an atomizing device), which can be calibrated so that the delivery of a specified amount of the active ingredient (s) is possible.
• Powder preparations can, for example, be sprayed into the nose from a capsule provided with small holes with the aid of an air flow generated, for example, by a rubber ball. All forms of preparation can represent multi-dose containers or divided single-dose containers.
• Nanoparticle suspensions can be obtained by grinding powdered constituents of the compositions according to the invention or by finely divided precipitation from solutions of constituents of the formulations according to the invention and generally have improved solubility properties.
• compositions according to the invention When formulated in liquid form, the compositions according to the invention contain solvents and, if appropriate, one or more auxiliaries such as, for example, buffers or substances for adjusting the pH, substances which increase viscosity, preservatives, surfactants, solubilizers, isotonizing agents, antioxidants and / or flavorings.
• auxiliaries such as, for example, buffers or substances for adjusting the pH, substances which increase viscosity, preservatives, surfactants, solubilizers, isotonizing agents, antioxidants and / or flavorings.
• water, glycerol, polyethylene glycol, propylene glycol or medium-strength triglycerides can be used as solvents.
• liquid formulations of the invention are preferred.
• this can be done by adding lactic acid (lactate), acetate, phosphate or citrate buffers or by adding methanesulfonic acid, hydrochloric acid, sulfuric acid, toluenesulfonic acid, gluconic acid, glucuronic acid, lactobionic acid, nitric acid, sodium hydroxide, potassium hydroxide , Sodium carbonate or trometamol can be achieved.
• Viscosity-increasing auxiliaries are, for example, polymers such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxyethyl cellulose,
• concentration of viscosity-increasing auxiliaries in the compositions according to the invention can depend on the substance used and the desired viscosity of the compositions according to the invention
• compositions according to the invention can contain one or more preservatives such as, for example, benzalkonium chloride, sorbic acid or its salts or benzoic acid or its salts, parabens such as methylparaben or propylparaben, chlorobutanol or thiomersal.
• preservatives such as, for example, benzalkonium chloride, sorbic acid or its salts or benzoic acid or its salts, parabens such as methylparaben or propylparaben, chlorobutanol or thiomersal.
• Preservatives in the compositions according to the invention can be selected depending on the substance used and the desired application. Typically, a preservative, if used, is present in the compositions of the invention in a concentration of up to 2% (m / v).
• the compositions according to the invention can also contain one or more surfactants and or solubilizers in order to increase the solubility of the cGMP PDE inhibitor used, if necessary.
• polysorbates polyethyleneglycol, polyoxyethylene derivatives of fatty acid half esters of sorbitol anhydrides such as, for example, Tweeen 80, polyoxyl 40 stearate, polyoxyethylene 50 stearate, bile salts, octoxynol, polyoxyethylated castor oil, polyoxystearate, poloxamers, phospholipids, phospholipids, phospholipids , Vaniline, urea, nicotinamide, cyclodextrins or cyclodextrin ethers can be used.
• nonionic, anionic or cationic additives of the above category can be used.
• concentration of the surfactants and / or solubilizers in the compositions according to the invention can be selected depending on the substance used and the desired application.
• a surfactant and / or solubilizer, if used, is present in the compositions of the invention in a concentration from 0.001% (m / v) to about 5% (m / v).
• compositions according to the invention can also contain one or more isotonizing agents.
• Mannitol or glucose can be used for this.
• concentration of isotonization rankings in the compositions according to the invention can be selected depending on the substance used and the desired application.
• an isotonizing agent, if used, is present in the compositions of the invention at a concentration of from 0.001% (m / v) to about 5% (m / v).
• the compositions according to the invention can also contain one or more antioxidants.
• antioxidants sodium metabisulfite, sodium bisulfite, ascorbic acid and salts thereof, butylated hydroxytoluene, butylated hydroxyanisole, metal chelators such as ethylenediaminetetraacetic acid, butylated hydroxyanisole, propyl gallate, ascorbyl palmitate or tocopherol can be used for this purpose.
• the concentration of the antioxidants in the compositions according to the invention can be chosen depending on the substance used and the desired application. An antioxidant, if used, is typically present in the compositions according to the invention in a concentration of 0.001% (m / v) to about 5% (m / v).
• compositions according to the invention can also contain one or more flavorings.
• flavorings for example saccharin sodium, aspartame, acesulfame
• Potassium or menthol can be used for this.
• concentration of the flavors in the compositions according to the invention can be chosen depending on the substance used and the desired application.
• a flavoring, if used, is present in the compositions of the invention in a concentration from 0.001% (m / v) to about 5% (m / v).
• compositions according to the invention are administered in the form of pressurized gas packs
• these pressurized gas packs also contain propellant gases such as, for example, propane, butane, nitrogen or nitrous oxide.
• propellant gases such as, for example, propane, butane, nitrogen or nitrous oxide.
• compositions according to the invention in powder form also contain carriers such as, for example, glucose, sucrose, mannitol, crystalline cellulose or lactose.
• compositions according to the invention in powder form can furthermore contain substances for prolonging the contact time with the nasal mucosa, for example polymers such as carbomer, chitosan or cellulose ether.
• concentration of these auxiliaries in the compositions according to the invention can be selected depending on the substance used and the desired application.
• such an adjuvant, if used, is present in the compositions of the invention in a concentration from 0.001% (m / v) to about 5% (m / v).
• compositions according to the invention can also contain moisturizers in order to prevent or reduce drying out of the mucosal membrane and thus to avoid irritation thereof.
• moisturizers for example, according to the present invention, sorbitol, propylene glycol or glycerin can be used for this.
• concentration of the wetting agents in the compositions according to the invention can be selected depending on the substance used and the desired application. Typically, a wetting agent, if used, is present in the compositions of the invention at a concentration of from 0.001% (m / v) to about 5% (m / v).
• Soluble formulations can be prepared in a simple manner by dissolving the ingredients in the chosen solvent, then filtering the solution, filling it in the containers provided under aseptic conditions and, if necessary, heat sterilizing it.
• the cGMP PDE inhibitor can be used in the form of the salt selected for the formulation.
• the free base can be added to the above solution together with a corresponding acid, so that the corresponding salt only forms in the solution.
• the subsequent further processing is carried out analogously to the procedure described above.
• the cGMP PDE inhibitor vardenafil can be added to the above solution in the form of its hydrochloride trihydrate or as a free base together with hydrochloric acid.
• compositions according to the invention may be advantageous to formulate as a powder.
• Purified water means purified water in the sense of the European Pharmacopoeia (Ph. Eur.), which is known to the person skilled in the art. It is demineralized water of standardized quality. example 1
• Comparative example 1 A solution was prepared analogously to Example 1, but with the benoxinate
• 100 ⁇ l of this solution were filled together with an excess of 20% into the product container of a single-dose nasal spray applicator and heat sterilized at a temperature of more than 121 ° C. for 15 minutes.
• the product container was then installed in a single dose nasal spray applicator. After actuating the applicator, 100 ⁇ l solution (which is 2 mg of the cGMP PDE- Inhibitors corresponds) as an aerosol.
• Methanesulfonic acid 1 0.902 - 1,000 g
• the ingredients are dissolved in water, filtered, filled with 120 ⁇ l each in plastic tubes and heat sterilized. 100 ⁇ l of solution corresponding to a single dose of 2 mg of the cGMP PDE inhibitor used can be removed per tube and administered nasally.
• 100 ⁇ l of this solution were filled together with an excess of 25% in single dose nasal spray applicators, sealed and heat sterilized at a temperature of 121 ° C. for 15 minutes. After actuating the applicator, 100 ⁇ l solution (corresponding to 1 mg vardenafil) are dispensed as an aerosol.
• Methanesulfonic acid 0.492-0.590 g purified water 96.428-96.33 g
• the solution was filtered through a 0.2 ⁇ m filter and, together with an excess of 30%, filled into 50 ⁇ l in single-dose nasal spray applicators, sealed and heat-sterilized at a temperature of 121 ° C. for 15 minutes. After actuating the applicator, 50 ⁇ l solution (corresponding to 1 mg vardenafil) is dispensed as an aerosol.
• 50 ⁇ l solution corresponding to 1 mg vardenafil
• Test 1 Comparative pharmacokinetics in dogs
• AUC norm AUC divided by the dose applied (mg per kg body weight)
• Cmax, norm maximum active substance concentration in the plasma divided by the administered

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Otolaryngology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pulmonology (AREA)
• Anesthesiology (AREA)
• Reproductive Health (AREA)
• Endocrinology (AREA)
• Gynecology & Obstetrics (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7681379

Family Applications (1)

Country Status (25)

Families Citing this family (16)

Family Cites Families (13)

• 2001
  • 2001-04-12 DE DE10118306A patent/DE10118306A1/de not_active Withdrawn
• 2002
  • 2002-04-03 RU RU2003133143/15A patent/RU2003133143A/ru not_active Application Discontinuation
  • 2002-04-03 CZ CZ20032752A patent/CZ20032752A3/cs unknown
  • 2002-04-03 WO PCT/EP2002/003663 patent/WO2002083674A2/de not_active Application Discontinuation
  • 2002-04-03 JP JP2002581429A patent/JP2004525968A/ja active Pending
  • 2002-04-03 IL IL15825502A patent/IL158255A0/xx unknown
  • 2002-04-03 CA CA002443639A patent/CA2443639A1/en not_active Abandoned
  • 2002-04-03 BR BR0208813-4A patent/BR0208813A/pt not_active Application Discontinuation
  • 2002-04-03 KR KR10-2003-7013280A patent/KR20030087072A/ko not_active Application Discontinuation
  • 2002-04-03 PL PL02363033A patent/PL363033A1/xx not_active Application Discontinuation
  • 2002-04-03 EE EEP200300501A patent/EE200300501A/xx unknown
  • 2002-04-03 MX MXPA03009314A patent/MXPA03009314A/es unknown
  • 2002-04-03 HU HU0303877A patent/HUP0303877A3/hu unknown
  • 2002-04-03 CN CNA028114574A patent/CN1537004A/zh active Pending
  • 2002-04-03 EP EP02732548A patent/EP1381368A2/de not_active Withdrawn
  • 2002-04-03 SK SK1268-2003A patent/SK12682003A3/sk unknown
  • 2002-04-04 DO DO2002000373A patent/DOP2002000373A/es unknown
  • 2002-04-10 AR ARP020101322A patent/AR035821A1/es not_active Application Discontinuation
  • 2002-04-11 GT GT200200070A patent/GT200200070A/es unknown
  • 2002-04-11 UY UY27256A patent/UY27256A1/es not_active Application Discontinuation
  • 2002-04-11 US US10/122,694 patent/US6740306B2/en not_active Expired - Fee Related
  • 2002-04-11 PE PE2002000303A patent/PE20021035A1/es not_active Application Discontinuation
• 2003
  • 2003-10-08 EC EC2003004795A patent/ECSP034795A/es unknown
  • 2003-10-09 BG BG108245A patent/BG108245A/bg unknown
  • 2003-10-10 NO NO20034556A patent/NO20034556L/no not_active Application Discontinuation
• 2004
  • 2004-03-30 US US10/813,801 patent/US20040248891A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events